92% of evaluable patients at interim analysis treated with RAD 101 achieved concordance¹ with MRI imaging (the primary endpoint) with significant and selective tumor uptake in suspected or recurrent ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, announced today publication of MRI imaging ...

BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...

Contrast-enhanced in-phase Dixon sequence could reduce the need for correlation among other imaging modalities to better identify areas of prior biopsy during breast MRI interpretation, according to a ...

RAD 101 demonstrated significant tumor uptake and 92% concordance with MRI in a phase 2b trial, enhancing confidence in its diagnostic potential. The agent targets fatty acid synthase, aiding in ...

Cancer imaging is entering a phase where malignant cells no longer hide in murky grayscale but flare into view with surgical ...

MRI contrast agents, which are typically gadolinium-based, are used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue. This ...

Radiopharm Theranostics shares rise after interim Phase 2b data showed 92% MRI concordance for RAD 101 imaging in brain metastases.

Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional recurrence whether or not they underwent preoperative breast magnetic resonance ...

Leesburg, VA, September 14, 2022—According to ARRS’ American Journal of Roentgenology (AJR), the contrast-enhanced in-phase Dixon sequence could reduce the need for correlation among other imaging ...